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Introduction: This study was performed to evaluate the clinical
outcomes of surgery for stage I small cell lung cancer (SCLC).
Methods: The National Cancer Institute Surveillance Epidemiology
and End Results (SEER) database was analyzed to evaluate out-
comes for patients with SCLC treated from 1988 to 2004. Patients
with stage I disease were selected. Kaplan-Meier survival curves
were constructed for overall survival (OS) and cause-specific sur-
vival for patient strata based on type of surgery and radiation use or
nonuse. Although SEER does not provide chemotherapy details, it is
assumed that most, if not all, of these patients received systemic
therapy.
Results: A total of 1560 patients were identified as having stage I
SCLC. Median age was 70 years (range 27–94 years). Two hundred
forty-seven patients underwent lobectomy, 121 had local tumor
excision/ablation, 10 had a pneumonectomy, and surgery was un-
known in 21. One thousand one hundred sixty-one did not have any
cancer-directed surgery. Of those who had lobectomy, 205 (83%)
did not receive radiation therapy (RT), 38 (15%) did receive RT, and
use of RT was unknown in 4 (2%).
For those who had lobectomy without RT (n  205), 3- and
5-year OS was 58.1% (95% confidence interval [CI] 51.1–64.5%) and
50.3% (95% CI 43.1–57.1%), respectively. For those patients who had
a lobectomy with RT (n  38), 3- and 5-year OS was 64.9% (95% CI
45.5–78.9%) and 57.1% (95% CI 37.4–72.7%), respectively.
Conclusions: Surgery without RT seems to offer reasonable OS
outcomes in a cohort of stage I patients who undergo lobectomy.
These results should be considered with the understanding that
systemic therapy information and margin status are not available
from the SEER database.
(J Thorac Oncol. 2010;5: 215–219)
Small cell lung cancer (SCLC) accounts for 13 to 20% ofall lung cancers,1 with an estimated annual incidence of
22,000 to 34,000 cases per year.2 Staging is typically dichot-
omized to “limited” or “extensive” stage disease, with limited
stage disease typically defined as confined to the hemithorax
of origin, mediastinum, and supraclavicular lymph nodes and
able to be treated with a single radiotherapy port.3,4 More
recent studies and the National Comprehensive Cancer Net-
work guidelines5 use the American Joint Committee on Can-
cer tumor, node, metastasis staging for more precise stratifi-
cation of disease extent. The International Association for the
Study of Lung Cancer recommendations for staging of SCLC
also note the significance of T and N stage on survival.6
For very early stage disease, initial randomized data
favored the use of radiation versus surgery7; however, more
modern studies have noted reasonable survival in node-
negative patients who undergo resection and chemother-
apy.8–14 The Lung Cancer Study Group randomized trial
failed to show improved survival for surgery compared with
radiation after neoadjuvant therapy,15 but this study has been
criticized for using suboptimal chemotherapy, for excluding
peripheral nodules (which are assumed to be T1N0 disease),
and for allowance of subtotal resection in the surgical arm.16
In light of the above conflicting randomized and retro-
spective analyses, treatment for locally confined SCLC is the
subject of ongoing randomized trials.16 Currently, treatment
for limited stage SCLC typically involves a combination of
radiation and chemotherapy. However, for small lesions with-
out lymph node involvement, expert consensus has recom-
mended the consideration of curative-intent surgery.2 Na-
tional Comprehensive Cancer Network guidelines have also
recommended lobectomy and mediastinal lymph node dissec-
tion followed by chemotherapy as the preferred treatment in
patients who are clinically stage T1-2N0.5 The American
College of Chest Physicians guidelines noted that though
there was inadequate evidence to support any categorical
recommendation regarding surgery in early-stage patients,
the authors “favor surgery in patients with node-negative
disease with small tumor size (3 cm).”2 Mediastinoscopy,
head computed tomography or magnetic resonance imaging,
abdominal computed tomography, and bone scan should be
performed (level 1A recommendation), and platinum based
adjuvant chemotherapy was recommended (level 2C recom-
mendation).2
To assist in characterizing outcomes for patients with
stage I SCLC treated with surgical resection without radio-
therapy in the community, the National Cancer Institute
Surveillance, Epidemiology, and End Results (SEER) data-
base was investigated.17 The SEER database is a large na-
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tional cancer database that combines state and city cancer
registries that most recently involves 25% of the US cancer
population.
PATIENTS AND METHODS
Patient Selection
After waiver from the Yale University School of Med-
icine Human Investigation Committee, the National Cancer
Institute 1973–2004 SEER database was examined. Patients
from 1973 to 1987 were not included in this analysis because
they did not have adequate information regarding pathologic
staging and lymph node dissection. Histology and site of
disease are coded in SEER according to the International
Classification of Diseases (ICD) for Oncology, Edition 3
(ICD-O-3).18 Patients with SCLC (ICD-0-3 histology code
804.1) of the lung (ICD-0-3 site code c34.0-c34.9) treated
from 1988 to 2004 were analyzed.
Patients with stage I disease were selected. Although
SEER does not provide chemotherapy details, it is assumed
that almost all these patients received systemic therapy given
small cell histology.
Overall and Cause-Specific Survival
Survival curves were generated by the method of
Kaplan-Meier. Overall survival (OS) and cause-specific sur-
vivals were analyzed using Cox regression. Cause-specific
and OS curves included patients with less than 4 months of
survival. However, when performing a Cox proportional
hazards analysis for the risk of death, to account for periop-
erative death in the analysis of postoperative adjuvant radia-
tion therapy (RT) versus no adjuvant RT, regression was
performed with patients with less than 4 months survival
excluded. Central nervous system (CNS) brain radiation was
reported as delivered in 32 patients (2%), recommended but
unknown if administered in two patients (0.1%), not given in
438 patients (28%), and unknown in 1088 patients (70%).
Because of the large unknown reporting of CNS radiation,
and the possibility that those patients who were recorded as
not having undergone CNS radiation actually received CNS
radiation after the SEER registry window of data collection
(within 4–6 months of diagnosis), CNS radiation was not
included as a variable for analysis.
All statistical analysis was performed with STATA/SE
9.2 (Stata Corporation, College Station, TX).
RESULTS
A total of 1560 patients were identified as having stage
I SCLC (Table 1). Age range was 27 to 94 years, with a
median of 70 years, and 795 patients (51%) were men.
Most patients (1161, 74.4%) did not undergo any can-
cer-directed surgery. One hundred twenty-one patients
(7.8%) underwent a surgical excision less extensive than a
lobectomy (which included laser destruction, local tumor
destruction not specified, wedge resection, segmentectomy,
resection not otherwise specified, and local excision), 10
patients (0.6%) underwent pneumonectomy, and surgery was
unknown for 21 (1.3%).
A total of 247 patients (15.8%) underwent lobectomy. Of
the patients who underwent lobectomy, the age range was 40 to
89 years with a median age of 68 years, and 126 (51%) were
men. Of the 247 patients who underwent lobectomy, 205 pa-
tients (83%) did not receive chest RT, 38 (15%) did receive
external beam RT, and use of RT was unknown in 4 (1.6%).
For all patients who had a lobectomy regardless of
radiation use, 3- and 5-year OS was 58% (95% confidence
interval [CI] 51–64%) and 50% (95% CI 43–57%), respec-
tively (Figure 1, Table 2). For patients who had a lobectomy
and were not recorded as receiving adjuvant radiation, 3- and
5-year OS was 57.1% (95% CI 49.4–64.1%) and 49.1% (95%
CI 41.2–56.6%), respectively. For patients who had a lobectomy
FIGURE 1. Kaplan-Meier curve for overall survival (lobec-
tomy alone, node negative).
TABLE 1. Patient Characteristics—All Patients (n  1560)
Gender
Male 795 (51.0%)
Female 765 (49.0%)
Race
White 1342 (86.0%)
Black 139 (8.9%)
Asian/Pacific Islander 67 (4.3%)
American Indian/Alaska Native/unknown 12 (0.8%)
Surgery
No surgery 1161 (74.4%)
Local excision, tumor destruction, wedge resection,
segmental resection
121 (7.8%)
Lobectomy 247 (15.8%)
Pneumonectomy 10 (0.6%)
Unknown whether surgery performed or type of
surgery performed
21 (1.35%)
Radiation use
No radiation 797 (51.1%)
External beam radiation 713 (45.7%)
Radioisotope and/or brachytherapy implant 7 (0.4%)
Unknown whether radiation delivered or unknown
type of radiation
43 (2.8%)
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and did receive radiation, 3- and 5-year OS was 64.9% (95% CI
45.5–78.9%) and 57.1% (95% CI 37.4–72.7%), respectively.
The use of radiation after lobectomy was not significantly
associated with an increased survival compared with lobectomy
alone (p 0.90). This was not changed when excluding patients
with less than 4 months of follow-up (to adjust for the bias of
perioperative death) (p  0.66).
For those patients who had a pneumonectomy (n 10),
3- and 5-year OS were both 46% (95% CI 14–73%) with
wide CIs because of the small number of patients. For the 121
patients with local excision, tumor destruction, wedge resection,
or segmentectomy, 3- and 5-year OS was 47.9% (95% CI
38.8–57.3%) and 33.7% (95% CI 24.0–43.7%), respectively.
There were 1085 deaths in follow-up with 885 cancer
deaths, of which 720 were attributed to lung cancer. There
were 200 noncancer deaths. Lung cancer-specific and non-
cancer-specific survivals are listed in Table 2. The Kaplan-
Meier curve for lung cancer-specific survival is shown in
Figure 2. The use of radiation after lobectomy was not
associated with an improvement in lung cancer-specific death
(p  0.71). This was also not changed when excluding
patients with less than 4 months of follow-up (p 0.95). The
same can be said for noncancer-specific death (p  0.74 and
p  0.34).
Four hundred seventy-five patients were alive at last
follow-up. Median follow-up for patients alive was 22
months. The longest surviving patient was alive at 198
months after diagnosis.
DISCUSSION
Based on our analysis of the SEER database, surgery
without RT seems to offer reasonable survival in a cohort of
patients who undergo lobectomy and who are node negative.
Our study is limited by several important factors.
There are several unknown details regarding the intent
and method of RT. The selection bias in choosing patients for
radiation and/or surgery is unknown. Margin status, comor-
bidity, and indications for the use of radiotherapy are also
unknown. For example, if patients who received radiation
were more likely to have positive margins on resection, then
this theoretically would have biased our study against radia-
tion. Alternately, if patients with significant comorbid dis-
eases were less likely to be referred for RT, this theoretically
would have biased our study in favor of radiation. Specific
FIGURE 2. Kaplan-Meier curve for lung cancer-specific sur-
vival (lobectomy alone, node negative).
TABLE 2. 3- and 5-yr Overall Survival, Lung Cancer-Specific Survival, and Noncancer Survival, Calculated by the Method of
Kaplan and Meier
Overall Survival Lung Cancer-Specific Survival Noncancer-Specific Survival
3-yr OS
(95% CI)
5-yr OS
(95% CI)
3-yr LCSS
(95% CI)
5-yr LCSS
(95% CI)
3-yr NCSS
(95% CI)
5-yr NCSS
(95% CI)
All patients
(n  1560)
31.0% (28.4–33.6%) 21.1% (18.7–23.6%) 38.5% (35.6–41.3%) 30.7% (27.7–33.8%) 84.8% (81.9–87.3%) 75.4% (71.1–79.3%)
All lobectomy
(n  247)
58.1% (51.1–64.5%) 50.3% (43.1–57.1%) 67.2% (60.0–73.3%) 64.3% (57.0–70.1%) 89.2% (83.5–93.0%) 82.6% (75.1–88.0%)
Lobectomy
without external
beam radiation
(n  205)
57.1% (49.4–64.1%) 49.1% (41.2–56.6%) 67.0% (59.2–73.7%) 64.4% (55.3–70.6%) 87.6% (81.0–92.0%) 82.1% (73.9–87.9%)
Lobectomy
and external
beam radiation
(n  38)
64.9% (45.5–78.9%) 57.1% (37.4–72.7%) 70.9% (51.2–83.8%) a 96.1% (75.7–99.4%) 84.6% (58.4–94.9%)
Pneumonectomy
(n  10)
45.7% (14.3–73.0%) a 45.7% (14.3–73.0%) a b b
External beam
radiation alone
(n  636)
28.4% (24.5–32.5%) 14.9% (11.4–18.9%) 35.3% (30.8–39.8%) 24.0% (19.1–29.1%) 84.6% (79.8–88.3%) 69.9% (60.8–77.2%)
a No further events. 5 yr numbers are the same as 3 yr.
b No noncancer deaths seen.
OS, overall survival; LCSS, lung cancer-specific survival; CI, confidence interval.
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details regarding fields, dose, and intent of radiotherapy are
also not available in SEER. Radiation given to large radio-
therapy fields with elective mediastinal irradiation concurrent
with chemotherapy would be coded the same as an aborted
course of limited radiation to gross residual disease.
In addition, whether patients did or did not receive
chemotherapy is an important issue, although it is likely that
most patients did receive chemotherapy because its use is the
current standard of care in this chemoresponsive disease.
Another unknown is the extent to which imaging studies were
used to stage patients. Whether patients who underwent
surgery were more likely to have undergone more extensive
staging is unknown. Finally, there was no central pathology
review. However, SEER registry identification of SCLC has
high sensitivity (94.1%) and percent exact agreement (98%)
in independent review.19
Finally, limiting the clinical applicability of this study
is the fact that many of the identified patients were likely
treated with surgery without the knowledge that the tumors
were of small cell histology. In studies involving surgery as
the primary treatment, approximately half of the patients
were not diagnosed with SCLC preoperatively.20 The SEER
data does not provide this information, but it is likely that
many of the patients were similarly not suspected to have
SCLC until after a resection. In addition, patients in the SEER
database were staged based on all available information,
including pretreatment clinical findings, and also surgical
pathology specimens. For thoracic sites, presurgical staging
(versus postsurgical) was not available. This perhaps has
caused our results to be more favorable, because those pa-
tients with clinical stage I disease who subsequently had more
extensive disease found at surgery would not be included in
our analysis group and would be upstaged by the SEER
registrars.
Despite above limitations, the findings of this study
are consistent with previous retrospective studies8–13 and
modern prospective trials21 that seem to indicate that
patients who are able to undergo resection for localized
disease have improved OS compared with those who are
unable to undergo resection. The average 5-year survival
reported in other series for stage I SCLC after resection is
52% (range 37–76%),8,10,11,14,22–24 which is quite compara-
ble with the SEER data. The Veterans Administration Surgi-
cal Oncology Group reported on 148 patients who underwent
a potentially “curative” resection, and noted that resection
was definitely indicated in patients with T1N0 disease, with a
5-year survival rate of 59.9%.14 A prospective multimodality
trial showed a 100% local control rate in patients who had
neoadjuvant chemotherapy (cisplatin/etoposide) followed by
surgery in initially localized disease.21 However, as noted
previously, the only modern randomized trial that we are
aware of comparing surgery followed by radiotherapy to
radiotherapy after induction chemotherapy did not support
the use of surgery.15
The variability in the reported results of other studies is
likely due to differences in selection (proportion of incidental
SCLC, size, extent of staging, etc.). It must be emphasized
that “resectable” SCLC represents only a small proportion of
patients with SCLC, which tends to magnify the effects of
selection. Other studies have also shown that only about 10%
of all patients with SCLC have been included in studies using
primary surgical treatment (all stages, but mostly I and II).24–26
This is compatible with our analysis of the SEER data, where we
found that only 16.5% of patients with stage I cancer underwent
lobectomy (15.8%) or pneumonectomy (0.6%).
This study reports data on more than 1500 patients, and
represents national practice patterns and outcomes, and thus
provides further insight into the role of surgery. Based on our
analysis, surgery does seem to have a role in the treatment of
localized disease, although this should be the subject of
continued clinical study and randomized clinical trials.
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